"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 22 | 14 | 36 |
| 1997 | 25 | 15 | 40 |
| 1998 | 36 | 12 | 48 |
| 1999 | 27 | 18 | 45 |
| 2000 | 14 | 12 | 26 |
| 2001 | 19 | 13 | 32 |
| 2002 | 8 | 5 | 13 |
| 2003 | 18 | 8 | 26 |
| 2004 | 13 | 15 | 28 |
| 2005 | 14 | 10 | 24 |
| 2006 | 19 | 13 | 32 |
| 2007 | 9 | 10 | 19 |
| 2008 | 8 | 13 | 21 |
| 2009 | 12 | 10 | 22 |
| 2010 | 13 | 13 | 26 |
| 2011 | 11 | 8 | 19 |
| 2012 | 12 | 11 | 23 |
| 2013 | 17 | 14 | 31 |
| 2014 | 18 | 9 | 27 |
| 2015 | 4 | 12 | 16 |
| 2016 | 13 | 9 | 22 |
| 2017 | 11 | 6 | 17 |
| 2018 | 8 | 7 | 15 |
| 2019 | 8 | 12 | 20 |
| 2020 | 7 | 10 | 17 |
| 2021 | 7 | 6 | 13 |
| 2022 | 1 | 7 | 8 |
| 2023 | 1 | 9 | 10 |
| 2024 | 5 | 8 | 13 |
| 2025 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. Inflamm Bowel Dis. 2025 Oct 01; 31(10):2714-2724.
-
AASLD AST Practice Guideline on adult liver transplantation: Diagnosis and management of graft-related complications. Liver Transpl. 2026 Mar 01; 32(3):444-490.
-
The position of anti-tumor necrosis factor agents for the treatment of adult patients with Crohn's disease. Expert Rev Gastroenterol Hepatol. 2025 Jul; 19(7):725-743.
-
Therapeutic Choices in Systemic Sclerosis-Associated Interstitial Lung Disease, a Survey of 2 International Research Groups. J Clin Rheumatol. 2025 Oct 01; 31(7):284-287.
-
PTPN2 and Leukopenia in Individuals With Normal TPMT and NUDT15 Metabolizer Status Taking Azathioprine. Clin Transl Sci. 2025 Jun; 18(6):e70220.
-
Belatacept as an alternative immunosuppressive agent for bone marrow-sparing in idiopathic pulmonary fibrosis lung transplant recipients with short telomeres. J Heart Lung Transplant. 2025 Oct; 44(10):1659-1662.
-
Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome. Arthritis Rheumatol. 2025 May; 77(5):606-614.
-
Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis. Front Immunol. 2024; 15:1499478.
-
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2025 Apr; 77(4):504-512.
-
Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients. Clin Transplant. 2024 Dec; 38(12):e70033.